Tower Bridge Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Tower Bridge Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,875	Closed	-$528K	–	268
2021 Q2	$528K	Hold	2,875	–	–	0.04%	187
2021 Q1	$440K	Sell	2,875 -340	-11%	-$52.6K	0.03%	186
2020 Q4	$502K	Buy	+3,215	New	+$413K	0.04%	174

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Tower Bridge Advisors's ALXN Position: Q3 2021 in Review

Tower Bridge Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,875 shares — an estimated $528K sold.

Tower Bridge Advisors first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $528K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Tower Bridge Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Tower Bridge Advisors sold 2,875 Alexion Pharmaceuticals shares in Q3 2021, an estimated $528K.
Tower Bridge Advisors first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Tower Bridge Advisors's Alexion Pharmaceuticals position peaked at $528K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Tower Bridge Advisors's 13F filing for Q3 2021, filed 28 Oct 2021.